Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site

Journal of Medicinal Chemistry

Volumn 41, Issue 3, 1998, Pages 393-400

  Kroemer, Romano T ^a   Koutsilieri, Eleni ^b   Hecht, Peter ^c   Liedl, Klaus R ^d   Riederer, Peter ^b   Kornhuber, Johannes ^e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Tripos GmbH   (Germany)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALAPROCLATE; AMANTADINE; BUDIPINE; DEFIBROTIDE; DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; DRUG CARRIER; ION CHANNEL; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ORPHENADRINE; PHENCYCLIDINE;

ARTICLE; BRAIN PROTECTION; DRUG DESIGN; DRUG SYNTHESIS; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; NEUROTOXICITY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BINDING SITES; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MOLECULAR STRUCTURE; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032576701     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9704412     Document Type: Article

References (43)

1. Olney, J. W. Excitotoxic amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 47-71.
2. 2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration. J. Neurosci. 1993, 13, 1993-2000.
3. Tymianski, M.; Charlton, M. P.; Carlen, P. L.; Tator, C. H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J. Neurosci. 1993, 13, 2085-2104.
4. Seeburg, P. H. The molecular biology of mammalian glutamate receptors. Trends Neurosci. 1993, 16, 359-365.
5. Cohen, B. D.; Rosenbaum, G.; Luby, E. D.; Gottlieb, J. S. Comparison of phencyclidine hydrochloride (sernyl) with other drugs. Simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl), lyseric acid diethylamide (LSD- 25), and amobarbital (amytal) sodium; II. Symbolic and sequential thinking. Arch. Gen. Psychiatry 1962, 6, 395-401.
6. Javitt, D. C.; Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148, 1301-1308.
7. Kornhuber, J.; Weller, M. In Schizophrenia - An integrated View; Alfred Benzon Symposium 38; Fog, R., Gerlach, J., Hemmingsen, R., Krogsgaard-Larsen, P., Thaysen, J. H., Eds.; Munksgaard: Copenhagen, 1995; pp 314-325.
8. Rosenbaum, G.; Cohen, B. D.; Luby, E. D.; Gottlieb, J. S.; Yelen, D. Comparison of sernyl with other drugs. Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception. Arch. Gen. Psychiatry 1959, 1, 651-656.
9. Kornhuber, J.; Weller, M. Psychotogenicity and NMDA receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry 1997, 41, 135-144.
10. Bigge, C. F. Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists. Biochem. Pharmacol. 1993, 45, 1547-1561.
11. Bigge, C. F.; Malone, T. C.; Hays, S. J.; Johnson, G.; Novak, P. M.; Lescosky, L. J.; Retz, D. M.; Ortwine, D. F.; Probert, A. W., Jr.; Coughenour, L. L.; Boxer, P. A.; Robichaud, L. J.; Brahce, L. J.; Shillis, J. L. Synthesis and pharmacological evaluation of 4a-phenantrenamine derivatives acting at the phencyclidine binding site of the N-methyl-D-aspartate receptor complex. J. Med. Chem. 1993, 36, 1977-1995.
12. Hays, S. J.; Novak, P. M.; Ortwine, D. F.; Bigge, C. F.; Colbry, N. L.; Johnson, G.; Lescosky, L. J.; Malone, T. C.; Michael, A.; Reily, M. D.; Coughenour, L. L.; Brahce, L. J.; Shillis, J. L.; Probert, A., Jr. Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor. J. Med. Chem. 1993, 36, 654- 670.
13. Nadler, V.; Kloog, Y.; Sokolovsky, M. Distinctive structural requirement for the binding of uncompetitive blockers (phencyclidine-like drugs) to the NMDA receptor. Eur. J. Pharmacol.-Mol. Pharmacol. Sect. 1990, 188, 97-104.
14. Reddy, N. L.; Hu, L.-Y.; Cotter, R. E.; Fischer, J. B.; Wong, W. J.; McBurney, R. N.; Weber, E.; Holmes, D. L.; Wong, S. T.; Prasad, R.; Keana, J. F. Synthesis and structure-activity studies of N,N′-diarylguandidine derivatives. N-(1-Naphthyl)-N′-(3- ethylphenyl)-N'-methylguanidine: A new, selective noncompetitive NMDA receptor antagonist. J. Med. Chem. 1994, 37, 260- 267.
15. Thurkauf, A.; Zenk, P. C.; Balster, R. L.; May, E. L.; George, C.; Carroll, F. I.; Mascarella, S. W.; Rice, K. C.; Jacobson, A. E.; Mattson, M. V. Synthesis, absolute configuration and molecular modeling study of etoxadrol, a potent phencyclidine-like agonist. J. Med. Chem. 1988, 31, 2257-2263.
16. Manallack, D. T.; Wong, M. G.; Costa, M.; Andrews, P.; Beart, P. M. Receptor site topographies for phencyclidine-like and sigma drugs: Predictions from quantitative conformational, electrostatic potential, and radioreceptor analyses. Mol. Pharmacol. 1988, 34, 863-879.
17. Leeson, P. D.; Carling, R. W.; James, K.; Smith, J. D.; Moore, K. W.; Wong, E. H. F.; Baker, R. Role of hydrogen bonding in ligand interaction with the N-methyl-D-aspartate receptor ion channel. J. Med. Chem. 1990, 33, 1296-1305.
18. Monn, J. A.; Thurkauf, A.; Mattson, M. V.; Jacobson, A. E.; Rice, K. C. Synthesis and structure-activity relationship of C5- substituted analogues of (±)-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine [(±)desmethyl-MK801]: Ligands for the NMDA receptor-coupled phencyclidine binding site. J. Med. Chem. 1990, 33, 1069-1076.
19. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
20. Kornhuber, J.; Herr, B.; Thome, J.; Riederer, P. The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue. J. Neural Transm. Suppl. 1995, 46, 131-137.
21. Kornhuber, J.; Parsons, C. G.; Hartmann, S.; Retz, W.; Kamolz, S.; Thome, J.; Riederer, P. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural Transm. Gen. Sect. 1995, 102, 237-246.
22. 3H]MK-801 binding sites in post-mortem human frontal cortex. Eur. J. Pharmacol. 1989, 162, 483-490.
23. Kornhuber, J.; Bormann, J.; Hübers, M.; Rusche, K.; Riederer, P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human post- mortem brain study. Eur. J. Pharmacol.-Mol. Pharmacol. Sect. 1991, 206, 297-300.
24. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 1989, 166, 589-590.
25. McPherson, G. A. A practical computer-based approach to the analysis of radioligand binding experiments. Comput. Prog. Biomed. 1983, 17, 107-114.
26. Munson, P. J.; Rodbard, D. LIGAND: a versatile computerized approach for the characterization of ligand-binding systems. Anal. Biochem. 1980, 107, 220-239.
27. Sybyl 6.2; Tripos Assoc.: St. Louis, MO, 1995.
28. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A new general purpose quantum chemical mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
29. QCPE: Quantum Chemistry Program Exchange, No. 455, MOPAC 6.0.
30. Martin, Y. C.; Bures, M. G.; Dahaner, E. A.; DeLazzer, J.; Lico, I.; Pavlik, P. A fast approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput.-Aided Mol. Des. 1993, 7, 83-102.
31. Brint, A.; Willett, P. Algorithms for the identification of 3-dimensional maximal common substructures. J. Chem. Inf. Comput. Sci. 1987, 27, 152-158.
32. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M., Jr.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
33. Clark, M.; Cramer, R. D., III; Van Opdenbosch, N. Validation of the general purpose Tripos 5.2 force field. J. Comput. Chem. 1989, 10, 982-1012.
34. Wold, S.; Albano, C.; Dunn, W. J.; Edlund, U.; Esbenson, K.; Geladi, P.; Hellberg, S.; Lindberg, W.; Sjöström, M. In Chemometrics: Mathematics and Statistics in Chemistry; Kowalski, B., Ed.; Reidel: Dordrecht, The Netherlands, 1984; pp 17-95.
35. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E. Crossvalidation, bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
36. Olney, J. W.; Price, M. T.; Labruyere, J.; Salles, K. S.; Friedrich, G.; Mueller, M.; Silverman, E. Anti-parkinsonian agents are phencyclidine agonists and N-methyl-D-aspartate antagonists. Eur. J. Pharmacol. 1987, 142, 319-320.
37. 2+ channels. Neurosci. Lett. 1989, 105, 227-232.
38. Parsons, C. G.; Quack, G.; Bresink, I.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Hartmann, S.; Danysz, W. Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 1995, 34, 1239-1258.
39. + channel cDNA. Neuropharmacology 1994, 33, 795-804.
40. Wilkinson, A.; Courtney, M.; Westlind-Danielsson, A.; Hallnemo, G.; Akerman, K. E. O. Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow. J. Pharmacol. Exp. Ther. 1995, 271, 1314-1319.
41. Ferrer-Montiel, A. V.; Sun, W.; Montai, M. Molecular design of the N-methyl-D-aspartate receptor binding site for phencyclidine and dizolcipine. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8021- 8025.
42. Antonov, S. M.; Johnson, J. W. Voltage-dependent interaction of open-channel blocking molecules with gating of NMDA receptors in rat cortical neurons. J. Physiol. 1996, 493, 425- 445.
43. Goldstein, S. A. N.; Colatsky, T. J. Ion channels: Too complex for rational drug design? Neuron 1996, 16, 913-919.